Synergy Pharmaceuticals Inc (SGYP)

2.91
0.01 0.34
NASDAQ : Health Care
Prev Close 2.90
Open 2.90
Day Low/High 2.89 / 3.01
52 Wk Low/High 2.50 / 9.76
Volume 3.90M
Avg Volume 4.70M
Exchange NASDAQ
Shares Outstanding 224.95M
Market Cap 672.62M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

First Week of SGYP August 18th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on Comcast, Synergy Pharmaceuticals, Chipotle, and Blackstone Group, but he's bearish on Sierra Wireless.

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Amazon wants to entertain and clothe -- and now feed -- every American. Cramer names the winners and the losers in this deal.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Remember the Rules of the Road

Remember the Rules of the Road

Diversification is the only risk management strategy that will work consistently.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

3 Beaten-Down Biotechs That Should Head Up

3 Beaten-Down Biotechs That Should Head Up

Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

New 52-Week Low Could Prompt More Insider Buying At SGYP

In trading on Wednesday, shares of Synergy Pharmaceuticals Inc touched a new 52-week low of $3.34/share. That's a $3.81 share price drop, or -53.29% decline from the 52-week high of $7.15 set back on 01/31/2017.

SGYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Synergy Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.18 "days to cover" versus the median component at 4.71. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Synergy Pharmaceuticals To Present At The Jefferies 2017 Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present a corporate update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 2:00 p.

Short Interest Moves 20.6% Lower For SGYP

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 14,132,134 share decrease in total short interest for Synergy Pharmaceuticals Inc , to 54,425,438, a decrease of 20.61% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Synergy Pharmaceuticals To Present Positive TRULANCE™ (Plecanatide) Phase 3 Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present late-breaking data from Phase 3 studies evaluating TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel...

Synergy Presents New Insights At Digestive Disease Week (DDW) Examining Patient And Physician Perceptions And Experiences With Chronic Idiopathic Constipation (CIC)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with managing their condition.

Synergy Pharmaceuticals To Present TRULANCE™ (Plecanatide) Phase 3 Data At Digestive Disease Week (DDW) For The Treatment Of Adults With Chronic Idiopathic Constipation (CIC) With Moderate To Very Severe Bloating

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present new data from an analysis of patients with moderate to very severe bloating at baseline who participated in two Phase 3 studies...

Synergy Pharmaceuticals To Highlight New Data For TRULANCE™ (Plecanatide) At Digestive Disease Week (DDW)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present six abstracts, including a late-breaker oral presentation showing new data on TRULANCE for the treatment of adults with irritable...

Synergy Pharmaceuticals To Present At The 42nd Annual Deutsche Bank Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present a corporate update at the 42 nd Annual Deutsche Bank Healthcare Conference in Boston on Wednesday, May 3, 2017 at 12:50 p.

Relative Strength Alert For Synergy Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Gary G. Gemignani, EVP And CFO, Synergy Pharmaceuticals Inc. (Photo: Business Wire)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary G.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Synergy Pharmaceuticals Announces Issuance Of Three New Patents Expected To Extend TRULANCE™ (Plecanatide) Patent Protection Until 2032

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents covering TRULANCE (plecanatide).

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.